

















































Mitochondrial autophagy, or mitophagy, is a key 
cellular pathway for mitochondrial quality  control  that  
 
 

















































functions to clear mitochondria [1-4]. Because the 
selective autophagosome-based mitochondrial 
degradation process eliminates unwanted or 
dysfunctional mitochondria after cell stress [5-9], 























Abstract:  Our  understanding  on  how  selective  mitochondrial  autophagy,  or  mitophagy,  can  sustain  the  archetypal









glycolysis‐  and  TCA‐related  metabolites  in  mitophagy‐deficient  iPSC  cells,  including  a  significant  decrease  in  the
intracellular levels of α‐ketoglutarate ‐a key suppressor of the differentiation path in stem cells. Mitophagy‐deficient iPSC
colonies  exhibited  a notably  reduced  teratoma‐initiating  capacity, but  fully  retained  their pluripotency  and multi‐germ
layer  differentiation  capacity  in  vivo.  PINK1‐dependent mitophagy  pathway  is  an  important mitochondrial  switch  that
determines  the  efficiency  and quality of  somatic  reprogramming.   Mitophagy‐driven mitochondrial  rejuvenation might
contribute  to  the  ability  of  iPSCs  to  suppress  differentiation  by  directing  bioenergetic  transition  and  metabolome
remodeling  traits.  These  findings  provide  new  insights  into  how mitophagy might  influence  the  stem  cell decisions  to
retain pluripotency or differentiate in tissue regeneration and aging, tumor growth, and regenerative medicine.  
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abnormal mitophagy has a deleterious impact on cell 
homeostasis and may lead to cell death, which causally 
contributes to the pathogenesis of degenerative 
disorders [10-16]. Although our knowledge of 
mitophagy in somatic cell physiology is extensive, the 
role of mitophagy in the physiology of stem cells, which 
have the unique ability to self-renew and differentiate 
into various cell types, is less understood. Thus, while 
mitophagy is believed to play a pivotal role in stem cell 
functions during aging, tissue regeneration, and cancer 
[17-24], our current understanding on how mitophagy 
can sustain the archetypal properties of stem cells is 
rudimentary. 
 
Mitochondria appear to play crucial roles during 
stemness factor-mediated nuclear reprogramming of 
somatic cells into induced pluripotent stem cells 
(iPSCs), a convenient “in a dish” model that allows a 
comprehensive understanding of stem cell biology. 
Functional metamorphosis of somatic oxidative 
phosphorylation into glycolytic metabolism plays a 
causal role in enabling the reprogramming process of 
acquisition and maintenance of stemness to occur [25-
35]. It is also apparent that the intrinsic metabolic 
demands that drive reprogramming to stemness involve 
substantial structural mitochondrial reorganization, 
transforming mitochondria into a cristae-poor, immature 
phenotype [36-45]. Paradoxically, the establishment of 
induced pluripotency requires a transient and early 
energy-demanding metabolic state characterized by 
increased mitochondrial oxidative phosphorylation and 
hyperactive mitophagy [46, 47]. Because the unique 
metabolic state required to achieve cell plasticity is 
accompanied by significant temporal changes in 
mitochondrial function, composition, structure, and 
maturation, it might appear elementary to suggest that 
mitophagy is a prerequisite of induced pluripotency. 
Nonetheless, recent studies have shed light on how 
interlinked processes critical for mitochondrial health, 
including mitochondrial fragmentation and mito-
chondrial fission/fusion, significantly alter the 
efficiency and speed of induced pluripotency [48-51], 
but little information is available on the role of 
mitophagy in the acquisition and maintenance of 
stemness.  
 
PTEN-induced putative kinase 1 (PINK1) encodes a key 
mitochondrial protein that specifically identifies and 
commits mitochondria to degradation via selective 
autophagy [52-63]. Using embryonic fibroblasts from 
PINK1 gene-knockout (KO) mice, we here tested the 
hypothesis that mitophagy is a pivotal mechanism of 
cell-fate plasticity by converting functionally mature 
mitochondrial networks into immature states and vice 
versa during nuclear reprogramming to stemness and 
commitment to differentiation, respectively. By 
examining the ability of mitophagy to causally 
modulate cell fate decisions during the entry to and exit 
from pluripotency, we have identified a hitherto 
unrecognized role of the mitophagy pathway as a 
critical mitochondrial switch that directs bioenergetic 
transition and metabolome remodeling traits to 
ultimately determine the efficiency and quality of 
nuclear reprogramming and stemness transition in 




PINK1-mediated mitophagy is necessary for efficient 
nuclear reprogramming of somatic cells into iPSCs 
 
Because the initial stages of reprogramming trigger a 
stress response involving repression of mitochondrial 
functions and oxidative stress [36-45, 66], we 
hypothesized that the critical ability of PINK1 to 
identify and selectively trim impaired mitochondria 
from the mitochondrial network might determine the 
efficiency of reprogramming. To test whether PINK1-
KO mouse embryonic fibroblasts (MEFs) constitute a 
useful model to dissect the role of mitophagy in the 
establishment of induced pluripotency, we first 
mimicked mitochondrial damage by experimentally 
depolarizing mitochondria with the uncoupler carbonyl 
cyanide m-chlorophenylhydrazone (CCCP) and then 
monitoring loss of MitoTracker staining after 
mitophagy stimulation [62, 67]. Collectively, our 
findings show that PINK1 is necessary to efficiently 
drive the mitophagic digestion of damaged 
mitochondria (Supplemental data; supplemental Fig. 1).  
 
We then used PINK1-/- MEFs to explore whether 
PINK1-mediated mitophagy might constitute part of the 
molecular roadmap facilitating reprogramming. To do 
this, we compared iPSC generation in early-passage 
PINK+/+ and PINK-/- MEFs using a three-factor 
induction protocol (Oct4, Sox2, and Klf4, hereafter 
referred to as OSK). We transduced MEFs with OSK at 
a 1:1:1 ratio on day 0 and repeated the transduction up 
to four times (one infection every 12 h using the same 
batch of all three retroviruses), after which the regular 
media was replaced with standard mESC media 
supplemented with the knockout serum replacement 
(KSR). As early as 7 days after transduction, clearly 
recognizable flat, packed, tight colonies characteristic of 
ES-like cells appeared in OSK-transduced PINK1+/+ 
MEF cultures (Fig. 1A). Conversely, OSK-transduced 
PINK1-/- MEFs mostly failed to display the typical 
compact ES cell colony morphology (Fig. 1A). Indeed, 
using a parallel live cell-imaging 96-well-plate-based 
screening assay to rapidly assess the expression of the 
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pluripotency-associated surface marker Ssea-1 during 
reprogramming, we found that the appearance of Ssea-
1+ clusters was delayed by 3-4 days in PINK1-/- MEFs 
compared with PINK1+/+ isogenic counterparts (data not 
shown). We combined the observations of ES cell-like 
morphological changes (e.g., defined boundaries and 
high nucleus-to-cytoplasm ratio within individual cells) 
with alkaline phosphatase (AP) activity, a commonly 
used pluripotency indicator, to quantify bona fide iPSC 
colonies. From 50,000 PINK1+/+ MEFs transduced, 
150±10 colonies were AP-positive at day 14 after 











































of 0.3% (Fig. 1A). In contrast, only 30±4 colonies were 
generated from an equivalent number of PINK1-/- 
MEFs, equivalent to an iPSC generation efficiency of 
0.06% (Fig. 1A). Concerning the transduction 
efficiency, we did not observe any significant 
differences between the two groups (data not shown), 
thus confirming that the observed decrease in 
reprogramming efficiency is due to the absence of 
PINK1. These findings show that loss of PINK1-
dependent mitophagy is sufficient to dramatically 













































Figure 1. Mitophagy deficiency  is  a  reprogramming barrier.  (A)  Early  passage  PINK1+/+  and  PINK1‐/‐ MEFs were  transduced with
retroviral vectors encoding for Oct4, Sox2, and Klf4 and cultured in ES medium. Phase‐contrast microphotographs of representative PINK1+/+
and  PINK1‐/‐ MEFs  at  day  7  (D7)  after  the  initial  transduction with OSK  are  shown  (white  arrows  indicate  emerging  iPSC‐like  colonies).
Representative photographs of colonies of AP‐stained OSK‐transduced PINK1+/+ and PINK1‐/‐ MEFs. The number of AP+ colonies was counted
14 days after  the  initial  infection and  represent  reprogramming efficiency  relative  to PINK1+/+ MEFs  (x‐fold)  (n=6  for each condition). **,
P<0.01. (B) Individual iPSC‐like colonies were randomly selected from each PINK1 subtype, cultured on 6‐well plates coated with MEF feeder
layers,  and  stained  either  for  AP  activity  (left)  or with  antibodies  against Oct3/4,  Nanog,  Sox2,  and  Ssea‐1  (right),  as  indicated  in  the
“Methods” section. Nuclear staining was performed with Hoechst 33258. Panel depicts  representative  images of  iPSC colonies  that were
captured using different  channels  for Oct3/4  (green), Nanog  (green), Sox2  (green), Ssea‐1  (green), or Hoechst 33258  (blue), as  specified.
Representative Western blots for Oct3/4 and Sox2 protein expression in PINK1+/+‐ PINK1‐/‐‐iPSCs are shown (middle; n = 2).  
  
www.impactaging.com                  1332                                           AGING, July 2016, Vol. 8 No.7
Loss of PINK1-mediated mitophagy destabilizes the 
undifferentiated state in iPSCs 
 
To verify that loss of PINK1-driven mitophagy 
dampens the reprogramming process, we picked 
random colonies from the previous experiment and 
established PINK1+/+-iPSC and PINK1-/--iPSC clonal 
cell lines on pre-seeded MEF feeder layers, which are 
known to encourage induced stem cells to remain in an 
undifferentiated state. Immunofluorescence staining 
analysis of early-passage iPSCs failed to reveal major 
differences in the expression level of Oct3/4, Nanog, 
Sox2, and Ssea-1 of individual cells within PINK1-/-- 
and PINK1+/+-iPSC colonies (Fig. 1B, right). Indeed, 
immunoblotting procedures demonstrated a similar 
expression profile of the pluripotency markers Oct3/4 
and Sox2 in early-passage PINK1-/-- and PINK1+/+-
iPSCs (Fig. 1B, middle). Both early- and late-passage 
PINK1+/+-iPSC colonies were large and well-rounded 
and stained strongly for AP, reflective of a high 
percentage of non-differentiated cells (Fig. 1B). The 
majority of relatively late-passage PINK1-/--iPSC 
colonies, however, were slightly smaller upon colony 
expansion, with very few showing a smooth, circular 
and distinct edge, and in many cases displaying 
irregular morphologies and undefined edges. Indeed, 
late-passage PINK1-/--iPSC colonies tended to rapidly 
lose AP activity and failed to stably retain the compact 
colony morphology typical of undifferentiated iPSCs 
[50, 68] (Fig. 1B, right).  
 
Given that the apparent destabilization of the 
undifferentiated state of PINK1-/--iPSCs occurred 
without drastic changes in the expression of several 
pluripotency markers, we explored whether loss of 
PINK1-driven mitophagy significantly altered the well-
known ability of nuclear reprogramming to transform 
the mitochondrial infrastructure and induce iPSC-
associated bioenergetic transition and metabolome 
remodeling traits [30]. 
 
Mitophagy deficient-iPSCs cannot “rejuvenate” the 
morphological characteristics of the mitochondria 
network 
 
We first confirmed that loss of PINK1 induces a 
moderate mitochondrial fragmentation in MEFs [52] as 
well as a more prominent accumulation of 
mitochondrial aggregates due to impaired mitophagy 
(Fig. 2A). Given that cell reprogramming leads to 
mitochondrial structural and functional alterations 
described as “rejuvenation” [36-42, 44, 45, 66], we used 
transmission electron microscopy (TEM) to examine 
whether the decreased capacity of PINK1-/--iPSCs to 
maintain their undifferentiated state involves alterations 
in the morphology of the mitochondrial network. 
Although we could detect a small decrease in the length 
and area of mitochondria in PINK1-/- MEFs, together 
with an increase in the number of mitochondria per cell 
(Fig. 2B), the majority of mitochondria in both MEF 
populations had a similar morphology characterized by 
mature mitochondrial networks with tubular structures 
and densely-packed cristae (Fig. 2B).  
 
PINK1+/+-iPSC mitochondria exhibited a dramatically 
decreased long diameter and increased short diameter 
relative to PINK1-/- MEFs (Fig. 2B). Interestingly, 
though nuclear reprogramming of PINK1+/+-iPSCs led 
to the acquisition of an immature mitochondrial 
phenotype characterized by a rounded morphology with 
sparse cristae, it was noteworthy that reprogramming 
failed to fully reset the mitochondrial morphology of 
PINK1-/- MEFs to a bona fide embryonic-like state. 
Con-sequently, PINK1-/- iPSCs accumulated larger, 
irregular mitochondria containing different inclusions 
and more cristae (Fig. 2B). These findings, altogether, 
strongly suggest that mitophagy deficient-iPSCs fail to 
fully rejuvenate the morphological characteristics of the 
mitochondrial network.  
 
Loss of PINK1-driven mitophagy impairs the 
bioenergetic transition associated with nuclear 
reprogramming 
 
Mitochondrial rejuvenation is a key mechanism to 
protect cells from reprogramming factor-induced 
oxidative stress and reactive oxygen species (ROS) 
accumulation, a well-known roadblock to re-
programming [36-42, 44, 45, 66]. We therefore 
speculated that blockade of PINK1-driven mitophagy 
might lead to a detrimental accumulation of ROS during 
the initial stages of reprogramming (Supplemental data; 
supplemental Fig. 2). Only when forced expression of c-
Myc, which can override the cell cycle checkpoints 
imposed in response to ROS accumulation [69-71], was 
combined with the exogenous addition of vitamin C 
PINK1-/- MEFs reached reprogramming efficiencies 
equivalent to those observed in OSK-transduced 
PINK1+/+ MEFs in the absence of this antioxidant 
(Supplemental data; supplemental Fig. 2). Because the 
incapacity of the ROS scavenger and epigenetic 
regulator vitamin C [72-75] to fully bypass the 
reprogramming roadblock imposed by the loss of 
PINK1 suggested that mitophagy-driven remodeling of 
the mitochondria network into an immature state might 
constitute a critical barrier during somatic reprogram-
ming, we performed a multimodal metabolic 
characterization of PINK1-/- and PINK1+/+ iPSCs at the 
level of cellular bioenergetics and intracellular 
metabolome. 
  


















































First, a well-validated extracellular flux technology was 
employed to establish functional monitoring of cellular 
bioenergetics in PINK1-/- and PINK1+/+ iPSCs. 
Measurement of the extracellular acidification rate 
(ECAR) enabled real-time assessment of the glycolytic 


















































supplementation of the glycolytic fuel glucose, the ATP 
synthase complex V mitochondrial inhibitor oligo-
mycin, and the competitive inhibitor of glucose 2-
deoxy-glucose (2-DG), dissected key parameters of 
glycolytic function, including glycolysis (i.e., the ECAR 
rate reached by iPSCs after the addition of saturating 
Figure 2. Mitophagy deficiency  impedes the rejuvenation of mitochondria networks  in  iPSCs.    (A) Loss of
PINK1  induces moderate mitochondrial  fragmentation and aggregation  in MEFs  (MT: MitoTracker). Bar chart depicts
the average percentages of cells showing fragmentation and/or aggregation (n=3). *, P<0.05. (B) Representative TEM
images of mitochondria in all cell lines. PINK1+/+ and PINK1‐/‐ MEFs display a preponderance of tubular and cristae‐rich
mature  mitochondria.  PINK1+/+  iPSCs  display  a  preponderance  of  “rejuvenated”  spherical  cristae‐poor  immature
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amounts of glucose), glycolytic capacity (i.e., the 
maximum ECAR rate reached upon blockade of 
oxidative phosphorylation), and glycolytic reserve 
(i.e., the capability of iPSCs to respond to an energetic 
demand). PINK1-/--iPSCs were found to be 

















































(Fig. 3A), suggesting that the reduced capacity of 
mitophagy deficient-iPSCs to efficiently drive mito-
chondrial metamorphosis translate into a reduced 
capacity to bioenergetically transitioning from somatic 
cellular respiration to glycolysis during iPSC 



















































Calculated  glycolysis  (maximum  rate  measurement  before  oligomycin  injection  –  Last  rate  measurement  before  glucose
injection  [1]),  glycolytic  capacity  (maximum  rate measurement  after  oligomycin  injection  –  Last  rate measurement  before
glucose injection [2]), and glycolytic reserve (glycolytic capacity – glycolysis [3]) were calculated with normalized ECAR values in
PINK1+/+‐ and PINK1‐/‐  ‐iPSCs (n = 2). (B) Two‐dimensional PLS‐DA models to view the separation of the two groups (PINK1+/+‐
and PINK1‐/‐  ‐iPSCs)  following GC‐EI‐QTOF‐MS‐based metabolomic profiling.  (C) Metabolites  in PINK1+/+‐iPSCs were extracted
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Loss of PINK1-driven mitophagy impairs the 
metabolome remodeling associated with nuclear 
reprogramming 
 
We utilized our recently developed targeted 
metabolomics platform coupling gas chromatography 
with quadrupole time-of-flight mass spectrometry and 
an electron impact source (GC-EI-QTOF-MS), which 
allows the simultaneous measurement of selected 
metabolites representative of the catabolic and anabolic 
status of key metabolic nodes. These metabolites 
include not only representatives of glycolysis and the 
mitochondrial tricarboxylic acid (TCA) cycle, but also 
other biosynthetic routes such as pentose phosphate 
pathway, amino acid metabolism and de novo fatty acid 
biogenesis [76, 77]. Metabolite-based clustering 
obtained by partial least squares-discriminant analysis 
(PLS-DA) model revealed a clear and significant 
separation between PINK1-/--iPSCs and PINK1+/+-
iPSCs in two-dimensional (2D) score plots (Fig. 3B). 
Profiling of the intracellular metabolome supported a 
PINK1-/- iPSCs signature distinct from the PINK1+/+ 
iPSCs counterpart, which apparently involved a notable 
decrease in a majority of the measured glycolysis- and 































Heatmap visualization, commonly used for 
unsupervised clustering, likewise revealed distinct 
segregation of metabolites in PINK1-/--iPSCs and 
PINK1+/+-iPSCs groups, pointing to an altered 
metabolic signature associated with the loss of PINK1-
dependent mitophagy in iPSCs (Fig. 4). Unsupervised 
hierarchical clustering of all pairwise comparisons 
among individual metabolites revealed several “hot 
spots” of highly correlated metabolites in a correlation 
matrix (Fig. 4). When VIP scores ≥ 1 in the PLS-DA 
model were used to maximize the difference of 
metabolic profiles between PINK1-/-- and PINK1+/+ -
iPSCs, the TCA metabolite α-ketoglutarate was the 
metabolite majorly impacted in mitophagy-deficient 
PINK1-/--iPSCs (Fig. 5). Quantitative assessment of 
metabolite concentrations confirmed that PINK1-/--
iPSCs significantly accumulated > 3-fold less α-
ketoglutarate than PINK1+/+-iPSCs (Table 1), 
suggesting that the reduced capacity of mitophagy 
deficient-iPSCs to efficiently drive mitochondrial 
metamorphosis during nuclear reprogramming translate 
into a reduced capacity to achieve the embryonic stem 
































Figure 4. Mitophagy deficiency  impairs  the metabolome  remodeling associated with nuclear  reprogramming.
Left.  Heatmap  to  view  the  agglomerative  hierarchical  clustering  of  the  PINK1+/+‐  and  PINK1‐/‐  ‐iPSCs  groups  analyzed with
MetaboAnalyst’s data annotation tool [103]. Rows: metabolites; columns: samples; color key  indicates metabolite expression


























































































































3-phosphoglycerate* 136.079 ± 16.415 77.173 ± 15.581 -1.76 
6-P-Gluconate* 11.045 ± 3.159 5.715 ± 0.397 -1.93 
α-ketoglutarate* 0.364 ± 0.111 0.116 ± 0.005 -3.14 
Alanine 2.435 ± 1.029 1.415 ± 0.335 -1.72 
Aspartate 102.883 ± 11.692 106.727 ± 3.873 1.04 
Citrate 4.533 ± 0.531 5.104 ± 1.146 1.13 
Fructose 1,6-BisP* 144.329 ± 29.863 80.327 ± 20.233 -1.80 
Fructose 6-P* 12.079 ± 2.511 5.499 ± 0.759 -2.20 
Fumarate* 1.814 ± 0.389 1.130 ± 0.116 -1.61 
Glucose* 40.668 ± 7.493 20.546 ± 6.196 -1.98 
Glucose 6-P* 9.085 ± 1.600 5.877 ± 0.587 -1.55 
Glutamate* 338.181 ± 2.622 322.962 ± 0.710 -1.05 
Glutamine 5.122 ± 0.630 5.643 ± 1.159 1.10 
Glyceraldehyde 3-P 54.602 ± 5.824 55.356 ± 7.668 1.01 
Isoleucine 24.623 ± 7.773 25.745 ± 5.453 1.05 
Lactate 212.007 ± 24.712 182.187 ± 18.347 -1.16 
Leucine* ULOQ 4.693 ± 1.384 - 
Malate* 10.379 ± 3.172 4.824 ± 0.693 -2.15 
Malonyl-CoA 24.615 ± 3.858 25.290 ± 2.881 1.03 
Phosphoenolpyruvate* 0.315 ± 0.124 0.541 ± 0.134 1.72 
Pyruvate 2.245 ± 0.946 2.136 ± 0.443 -1.05 
Ribose 5-P* 6.136 ± 1.768 4.286 ± 0.499 -1.43 
Serine* 36.239 ± 1.181 22.870 ± 0.448 -1.59 
Succinate 35.714 ± 3.785 34.638 ± 5.498 -1.03 
Succinyl-CoA 1.142 ± 0.296 1.044 ± 0.341 -1.09 









































Mitophagy-deficient iPSC colonies exhibit a 
significantly reduced teratoma-initiating capacity 
 
The ability to derive the three germ layers generated 
during development, (ectoderm, mesoderm and 
endoderm), is the gold standard for determining 
whether potential iPSC candidates are fully pluripotent 
[78-80]. We thus examined the teratoma initiating and 
differentiation potential of PINK1+/+- and PINK1-/--
iPSCs in vivo. To exclude the possibility that any 
uncoupling of pluripotent capacity from tumorigenesis 
might be dose-dependent, i.e., with differentiation 
occurring at lower cell doses but tumors forming at 
higher cell doses, we injected 4- to 5-week-old 
athymic nude mice subcutaneously either with 5 x 105 
undifferentiated iPSCs or with 2 x 106 cells, the latter 
being a saturating concentration to ensure the 
development of teratoma masses within a few weeks 





































histology of teratoma composition. The rate of teratoma 
formation in PINK1+/+-iPSCs was 100% (6/6 mice in 
each group) regardless of the number of cells injected 
(Fig. 6A). In contrast, we observed a cell number-
independent reduction in the rate of teratoma formation 
following the injection of PINK1-/--iPSCs (60%; 4/6 
mice in each group). Thus, the time required for 50% of 
animals to develop palpable teratomas was lengthened 
by 161% (from 26 to 68 days) upon injection of 5 x 105 
PINK1-/--iPSCs, and by 166% (from 21 to 56 days) 
upon injection of 2 x 106 PINK1-/--iPSCs in (Fig. 6A). 
Indeed, injection of PINK1-/--iPSCs resulted in 
drastically smaller teratomas than those observed upon 
injection of PINK+/+-iPSCs, i.e., the lesions in PINK1-/--
iPSC-injected mice were 15-fold smaller in size 
compared to the mean teratoma size observed in the 
PINK+/+-iPSC group (78 mm3 versus 1166 mm3, 
respectively) (Fig. 6B).  
Figure 5. α‐ketoglutarate  is the most  impacted metabolite  in mitophagy deficient‐iPSCs.






















































Mitophagy-deficient iPSC colonies retain 
pluripotency and multi-germ layer differentiation 
potential 
 
Given the above results, it might be argued that 


















































dependent mitophagy was due to the failure of PINK1-/--
iPSCs to differentiate into primitive tissues representing 
all three germ layers. To question this, we carried out an 
ultrastructure analysis of teratomas from both groups of 
mice. Despite the lower efficiency in teratoma 
formation and the longer latency, tissue composition of 
Figure 6. Mitophagy deficiency reduces tumorigenicity of iPSC colonies. Athymic mice were injected with 5 x 105 or 2 x
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PINK1-/--teratomas was not noticeably different from 
equivalent PINK+/+-teratomas at the histological level. 
Hematoxylin-eosin staining showed various tissue 
derivatives of the three germ layers, including neural 
rosettes (ectoderm), gut-like epithelial tissues 
(endoderm), and smooth muscle, adipocytes, bone, and 
cartilage (mesoderm), in both teratoma groups (Fig. 7), 
confirming the full pluripotency and multi-germ layer 
differentiation potential of the iPSCs regardless of the 
PINK1-mediated mitophagy status. These findings, 
together with the fact that PINK1-/--iPSCs normally 
expressed pluripotent markers confirmed that 
mitophagy-deficient iPSCs re-established pluripotency 









































Although PINK1+/+- and PINK1-/--iPSCs gave rise to 
teratomas composed of various recognizable tissue 
elements, we observed striking differences in the 
embryonal carcinoma (EC)-like component of poorly 
differentiated, primitive-appearing, blast-like 
teratocarcinoma stem cells. Accordingly, the large 
teratomas originating from PINK1+/+-iPSCs displayed 
extensive areas of undifferentiated tissue, e.g., abundant 
embryonic-appearing neuroepithelium with a high 
number of mitotic figures, which were considered as 
malignant based on the examination by a pathologist 
(Fig. 7). Conversely, PINK1-/--iPSCs developed 
teratomas consisting almost exclusively of fully 











































PINK1‐/‐‐iPSC‐derived  teratomas.  Representative  photographs  of  teratomas  (circled  with  white  dotted  lines)  are






tissue,  squamous  keratinized  epithelium,  skeletal  muscle  tissue,  mucinous  glands,  (e’)  Mature  nervous  tissue,
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logically benign, mature, and well-differentiated cystic 
lesions. Using TEM, we found that the cytoplasm of the 
extensive undifferentiated regions in PINK1+/+-iPSC-
generated teratomas exhibited a simple architecture 
typical of embryonic-like cells in the early stages of 
development. Consequently, these regions were devoid 
of most organelles except for the presence of numerous 
ribosomes, a well-developed Golgi apparatus, and rough 
endoplasmic reticulum (Fig. 8). These regions contained 
few mitochondria and, when found, presented a globular 
shape with poorly developed cristae and electron-lucid 
matrix, and perinuclear localization, all indicative of 










































tomas from PINK1-/--iPSCs generated tissues with 
conspicuous and numerous mitochondria, possessing a 
complex morphology with well-developed cristae, denser 
matrix, and elongated or branched appearance (Fig. 8).  
 
Although it might be argued that, because mitophagy-
deficient iPSC colonies tended to rapidly differentiate in 
vitro and exhibited a significantly reduced teratoma-
initiating capacity, the percentage of fully 
reprogrammed cells might be significantly lower within 
PINK1-/--iPSC colonies, these findings are also 
consistent with a more rapid differentiation of 












































Figure  8.  Mitophagy‐deficient  iPSC  colonies  are  prone  to  direct  differentiation  in  vivo.  Left.  Analyses  of
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DISCUSSION 
 
Here we provide the first demonstration that mitophagy 
is a necessary mechanism for the conversion of somatic 
cells to a pluripotent cell fate with maximum efficiency. 
Our discovery that mitophagy-driven mitochondrial 
rejuvenation is required for induction and maintenance 
of stem cell pluripotency and that the mitophagy 
pathway plays a critical mitochondrial switch that 
determines the efficiency and quality of somatic 
reprogramming, illustrates how mitophagy can play a 
pivotal role in stem cell functions during aging and 











































We first addressed the question of whether mitophagy is 
a crucial process during nuclear reprogramming. Our 
findings reveal that the sole loss of PINK1-dependent 
mitophagy was sufficient to dramatically decrease the 
efficiency (∼80% reduction) and speed of the nuclear 
reprogramming process (Fig. 9). Deficiency of PINK1-
regulated mitochondrial quality control constitutes a 
previously unrecognized barrier to reprogramming. This 
fact, taken together with recent studies showing that 
whereas activation of DRP1-driven mitochondrial 
fragmentation contributes to the acquisition and 
maintenance of stem cell pluripotency [48, 50], 














































epigenetic  landscape and decreasing  the size of  the stem cell state basin of attraction, which  results  in  the deceleration
(i.e.,  lower efficiency  and  slower  kinetics) of  the nuclear  reprogramming process.  This  conceptual  figure  represent  cells
stabilized  in  an  initial  non‐pluripotent,  somatic  attractor  and  how  nuclear  reprogramming  can  make  cells  exceed  the
“reprogramming  barriers”,  represented  as  a wall  of  interlocking  bricks,  easier  or  harder  in  the  presence  or  absence  of
PINK1‐dependent mitophagy,  respectively, and  fall down  in a  final attractor of  fully  reprogrammed,  induced pluripotent
stem cell states. The cellular reprogramming process is presented as a colored line from the initial to the final cellular state. 
  
www.impactaging.com                  1342                                           AGING, July 2016, Vol. 8 No.7
ordinately regulate mitochondrial fusion) instead elicits 
mitochondrial metabolic reprogramming to pluripotency 
[49], bolsters the notion that the ability of mitochondrial 
fission/fusion and mitophagy to restructure mito-
chondrial dynamics is central for the control of cell-fate 
plasticity. Accordingly, it was reported that a restricted 
2-day burst of autophagy (causing mitophagy) at the 
early stages of reprogramming was vital for iPSC 
generation [47].  
 
We next focused on whether mitophagy is the driving 
mechanism for the conversion of functionally mature 
mitochondria to an immature state and vice versa, 
during reprogramming to stemness and commitment to 
terminal differentiation, respectively. The fact that loss 
of PINK1-dependent mitophagy impeded the full 
rejuvenation of the mitochondrial network during 
reprogramming indicates that mitophagy operates as a 
key mechanism in generating the immature 
mitochondrial structure commonly found in stem cells. 
Because a high level of mitophagy has recently been 
found to be a requisite for the high quality of 
mitochondria required for the stem cell state [82], and 
given that the number of AP+ colonies during early 
stages of reprogramming is used as an initial indicator 
of successful reprogramming of cells, the fact that cells 
within PINK1-/- iPSC colonies appeared to inherit a 
mixture of mature (“old”) and immature (“young”) 
mitochondria when compared with PINK1+/+-iPSCs 
colonies whose cells almost exclusively inherited 
immature mitochondria might suggest that the ratio of 
fully reprogrammed colonies among AP+ colonies is 
significantly lower in the absence of PINK1-dependent 
mitophagy. Furthermore, because AP expression levels 
is a less sensitive measure to differentiate between 
undifferentiated and early differentiating cells, the fact 
that mitophagy-deficient iPSC colonies normally 
expressed the pluripotent markers Oct4 and Sox2 
together with their strong tendency to spontaneously 
differentiate and form heterogeneous populations of 
cells strongly suggest that PINK1-dependent mitophagy 
might be necessary for the iPSCs to remain in 
undifferentiated state. Indeed, with growing evidence 
for remodeling of energy metabolism in cell fate 
decisions, the fact that functional monitoring of cellular 
bioenergetics revealed an attenuated glycolytic capacity 
in mitophagy-deficient iPSC cells strongly suggest that 
the mitophagy pathway is an operating mechanism of 
mitochondrial switching that directs bioenergetic 
transition from somatic oxidative in somatic cells to 
glycolysis in iPSCs.  While mitophagy might ultimately 
determine the efficiency and quality of nuclear 
reprogramming and stemness transition in somatic cells 
by participating in the bioenergetic conversion for 
establishing functional pluripotency, it remains to be 
unambiguously defined whether the ultimate role of 
mitophagy in stem cells is to regulate the preferential, 
asymmetric apportion of younger mitochondria during 
self-renewal [82].    
 
The main characteristics of iPSC mitochondria are their 
rounded morphology with condensed cristae and their 
poor oxidative activity due to the low membrane 
potential [36-45, 65]. Given that mitophagy is triggered 
by mild oxidative stress in a mitochondrial fission-
dependent manner [83], we hypothesized that abnormal 
mitophagy might lead to the accumulation of “old”, 
ROS-generating mitochondria, and this, in turn, might 
impair the efficiency of reprogramming. Our results 
showed that the mitophagy deficiency-imposed 
roadblock for reprogramming is bypassed, in part, by 
the ROS scavenger vitamin C upon the inclusion of 
oncogenic c-Myc, which is a key inducer of glycolytic 
reconfiguration [31, 84]. Interestingly, c-Myc also 
functions as the major contributor of reprogramming-
mediated oxidative stress [38, 85]. Therefore, while it 
seems likely that ROS partially contribute to the lower 
reprogramming efficiency of PINK1-/- MEFs, other 
ROS-independent mitochondrial changes imposed by 
the loss of PINK1-driven mitophagy seem to operate as 
a dominant roadblock during reprogramming. Because 
histone demethylases have been shown to be the direct 
downstream effectors of vitamin C-dependent 
enhancement of cell reprogramming, in addition to its 
antioxidant activity [72-75], it is possible that 
mitophagy deficiency might impede reprogramming by 
inhibiting histone demethylation. In this regard, it was 
noteworthy that the iPSC metabolite majorly impacted 
by loss of PINK1-dependent mitophagy was α-
ketoglutarate, a key mitochondrial metabolite that is 
siphoned from the TCA cycle to support rapid cell 
proliferation via lipid and amino acid biosynthesis that 
can exit also the mitochondria to function as a cofactor 
for dioxygenase enzymes including Jumonji-family 
histone demethylases, TET-family DNA hydroxylases, 
and prolyl hydroxylases [86-88]. Indeed, the 
intracellular α-ketoglutarate levels have been shown to 
contribute to the maintenance of cellular identity and 
have a mechanistic role in the transcriptional and 
epigenetic state of stem cells [89]. Further research, 
however, is needed to evaluate the precise epigenetic 
modifications associated with mitophagy-related 
changes in mitochondrial biogenesis, structure, and 
function, i.e., how mitophagy might drive the 
acquisition and maintenance of stemness by meta-
bolically regulating the epigenetic landscape of the 
nuclear genome [90-92].  
 
The fact that PINK1-/--iPSCs possessed a normal 
capacity to differentiate into mature tissue confirmed 
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that deficiency of PINK1-driven mitophagy does not 
interfere with the pluripotent quality of iPSCs. Because 
the kinetics of teratoma formation is dependent on the 
number of remaining pluripotent stem cells during the 
differentiation procedure [93-98], it might be tempting 
to suggest that loss of PINK1-driven mitophagy 
facilitates the depletion of residual undifferentiated 
pluripotent cells (teratocarcinoma-initiating cells) 
during in vivo teratoma formation. Moreover, because 
the retention of the embryonal character is considered 
the basis for continuous and progressive growth of 
malignant teratomas, loss of biological aggressiveness 
in PINK1-/--iPSC-derived teratomas apparently suggest 
that mitophagy deficiency impedes the retention of 
undifferentiated pluripotent stem cells by promoting 
their differentiation and inhibiting potential 
dedifferentiation of committed cells. Accordingly, the 
highly significant more active mitochondrial state of 
tissues from PINK1-/- teratomas might be indicative of 
rapid, most committed differentiation of otherwise 
pluripotent PINK1-/--iPSCs. Conversely, it might be 
argued that these findings reflect that the percentage of 
fully reprogrammed cells might be significantly lower 
within mitophagy-deficient PINK1-/--iPSC colonies. 
Forthcoming studies should evaluate whether rapidly 
differentiating, mitophagy-deficient heterogeneous 
colonies of PINK1 KO-iPSCs might illuminate new 
mitochondria-centered mechanisms aimed to restore or 
stimulate a differentiation checkpoint capable of 
limiting the aberrant self-renewal of life-threatening 
cancer stem cells in tumor tissues.  
 
We are beginning to dissect the roles of mitochondria in 
the establishment and homeostasis of stemness, which 
may help to uncover novel insights into our 
understanding of a wide variety of degenerative 
diseases, aging, and aging-related diseases including 
cancer. Although we are still far from a comprehensive 
understanding of the physiological functions of 
mitochondria in stem cells, our findings extend previous 
studies into the causal mechanism behind the well-
recognized metabolic switch during the establishment of 
pluripotency, which is accompanied by significant 
changes in mitochondrial function, composition, 
structure, maturation, and signaling. Mitophagy appears 
to be a crucial cellular process for the conversion of 
functionally mature mitochondria to an immature state 
and vice versa during reprogramming and 
differentiation, respectively. In this regard, mitophagy 
may ensure a metabolic transition to meet the specific 
energetic and anabolic demands of the stemness state, 
e.g., mitophagy-induced repression of mitochondrial 
functions including mitochondrial clearance might 
accelerate the onset of the glycolytic metabolism [99]. 
Furthermore, mitophagy-driven mitochondrial rejuvena-
tion might contribute to the ability of stem cells to 
suppress differentiation by orchestrating the 
mitochondria function as signaling organelles of diverse 
biological functions [100, 101], including not only 
bioenergetic transitions but, perhaps more importantly, 
metabolome remodeling traits connecting mitochondrial 
metabolites with epigenetics [100-102]. Further studies 
are warranted to determine the causal role of 
mitophagy-driven mitochondrial rejuvenation as part of 
the mechanism involved in the maintenance and 
asymmetric transmission of the pluripotency and 
differentiation fate of stem cells. Our discovery that 
mitophagy-controlled mitochondrial quality is a critical 
director of cell-fate plasticity and stem-cell fate should 
provide new insights into how mitophagy might 
influence the stem cell decisions to retain pluripotency 
or differentiate in tissue regeneration and aging, tumor 
growth, and regenerative medicine. 
 
MATERIALS AND METHODS 
 
PINK1-knockout mouse embryonic fibroblasts.  PINK1-
knockout mice were generated by targeted deletion of 
exon 1 as described [52]. Loss of Pink1 mRNA 
expression in primary embryonic fibroblasts (MEFs) 
was confirmed by quantitative RT-PCR [52]. 
 
Generation of iPSCs. Mouse primary iPSCs were 
created by transducing MEFs deficient for PINK1 
(PINK1-/-) and wild-type (PINK1+/+) counterparts with 
the pMXs-based retroviruses that individually encode 
the mouse transcription factors Oct3/4, Sox2, and Klf4 
following a previously-described protocol [64, 65]. 
Characterization of iPSC-like colonies was carried out 
by analyzing pluripotent marker expression by alkaline 
phosphatase (AP) staining using the StemTAG™ 
Alkaline Phosphatase Staining and Activity Assay Kit 
(Cell Biolabs, Inc. Cat. No. CBA-302) and the 
expression of Oct3/4, Nanog, Sox2, and Ssea-1 by 
immunofluorescence (see below).  
 
To generate feeder-free iPSC cultures for teratoma 
assays, culture plates were coated with 0.3 mg/mL 
Matrigel (growth factor-reduced, BD Biosciences, San 
Jose, CA) at 4oC overnight. Unbound Matrigel was 
aspirated, and the cells were washed with DMEM/F12 
medium. iPSCs were seeded on Matrigel-coated plates 
in MEF-conditioned ES cell medium supplemented with 
leukemia inhibitory factor (LIF) and bFGF (4 ng/mL). 
The medium was changed every day.  
 
Immunofluorescence staining. High-content confocal 
imaging was performed in 96-well clear bottom 
imaging tissue culture plates (BD Biosciences) 
optimized for automated imaging applications. Triton® 
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X-100 permeabilization and blocking, primary antibody 
staining, secondary antibody staining using Alexa 
Fluor® 488 goat anti-rabbit/mouse IgG (Invitrogen, 
Molecular Probes, Eugene, OR) and counterstaining 
(Hoechst 33258; Invitrogen) were performed following 
BD Biosciences protocols. Images were captured in 
different channels for Alexa Fluor® 488 (pseudocolored 
green) and Hoechst 33258 (pseudocolored blue) on a 
BD PathwayTM 855 Bioimager System (BD 
Biosciences) with 20× or 40× objectives (NA 075, 
Olympus). Merged images were obtained according to 
the Recommended Assay Procedure using BD 
AttovisionTM software. 
 
Reactive Oxygen Species (ROS) detection. Cells were 
incubated for 60 min with 10 μmol/L 2’,7’-dihydro-
dichlorofluorescein-diacetate (H2DCF-DA) (Invitrogen, 
Molecular Probes) at 37˚C. Cellular green fluorescence 
was then measured by flow cytometry. Cell-permeant 
non-fluorescent H2DCF-DA, upon cleavage of the 
acetate moiety by intercellular esterases and oxidation 
by ROS, is converted to strongly fluorescent DCF and 
thus reports the ROS abundance. 
 
Immunoblotting. Equal concentration of proteins (50 
μg) was loaded into a 10% SDS-polyacrylamide gel and 
then electrotransferred. After blocking (5% nonfat 
powder milk in TBS plus 0.1% TritonX100 for 1 h at 
room temperature), the nitrocellulose membranes were 
incubated for 16-20 h at 4oC with the primary antibody 
(Oct3/4, Abcam ab-1985, 1:600; Sox2, Abcam ab-
97959, 1:1000; β-actin, Santa Cruz sc-47778; 1:500). 
The detection of the immune complexes after 
incubation with the appropriate peroxidase-conjugated 
secondary antibody (Cell Signaling #7074, 1:1000; 
Calbiochem #401215, 1:5000) was performed with the 
Clarity™ Western ECL Substrate (Bio-Rad).  
 
Extracellular flux bioenergetic assays. Extracellular 
acidification rates were measured using an XF 
Extracellular Flux Seahorse Analyzer (Seahorse 
Bioscience). XFp Glycolysis Stress tests were performed 
in accordance with manufacturer’s instructions. Each 
plotted value is the mean of at least 6 replicates and was 
normalized to Hoechst signal in each well.  
 
Targeted metabolomics and data analysis.  Measurements 
of bioenergetics metabolites obtained from PINK1+/+-
iPSC and PINK1-/--iPSC clonal cell lines were performed 
by employing a previously described simple and 
quantitative method based on gas chromatography 
coupled to quadrupole-time of flight mass spectrometry 
and an electron ionization interface (GC-EI-QTOF-MS) 
[76, 77].  
 
Raw data were processed and compounds were detected 
and quantified using the Qualitative and Quantitative 
Analysis B.06.00 software (Agilent Technologies), 
respectively. MetaboAnalyst 3.0 
(http://www.metaboanalyst.ca) was used to generate 
scores/loading plots, Heatmaps, and correlation maps 
[103]. 
 
Teratoma assays. To form teratomas, iPSCs were 
harvested from Matrigel-coated culture dishes and 
injected subcutaneously (s.c.) into the dorsal flank of 
female athymic nude mice (four- to five-weeks-old, 23-
25g; Harlan Laboratories, France). Mice were weighed 
once per week. Teratomas were measured daily with 
electronic calipers and tumour volumes were calculated 
using the formula: volume (mm3) = length × width2 × 
0.5. General health of the mice in response to teratoma 
development (e.g., subcutaneous teratomas cause 
ulceration on the skin) was monitored daily by a 
specialized veterinarian. Teratomas were carefully 
dissected and removed in entirety, fixed in 10% 
phosphate buffered formalin (3.6% formaldehyde) for 
24 hours, and paraffin-embedded. For histopathological 
analysis, consecutive sections (4 μm) were cut and 
stained with haematoxylin and eosin according to 
standard procedures. 
 
The Institutional Animal Care and Use Committee 
(IACUC) of the Institut d’Investigació Biomèdica de 
Bellvitge (IDIBELL; Animal Use Protocol #6302 
authorized by the Animal Experimental Commission 
from the Catalan Government, Barcelona, Spain) 
approved the experiments. 
 
Transmission electron microscopy. Small pieces of 
teratomas were fixed in a 2% glutaraldehyde solution in 
0.1 M cacodylate buffer, pH 7.4. Samples were then 
post-fixed in 1% osmium tetroxide (OsO4) for 2 h and 
dehydrated through a graded series of acetone prior to 
impregnation in increasing concentrations of resin in 
acetone over a 24 h period. Semi-thin sections (500 nm) 
were stained with 1% toluidine blue. Ultrathin sections 
(70 nm) were subsequently cut using a diamond knife, 
double-stained with uranyl acetate and lead citrate, and 
examined with a transmission electron microscope 
(Hitachi, Tokyo, Japan). 
 
Statistical analysis. The results are presented as the 
mean ± SD of at least three repeated individual 
experiments for each group. The analyses were 
performed using XLSTAT 2010 (AddinsoftTM). A P-
value ≤ 0.05 was considered statistically significant. 
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SUPPLEMENTAL DATA 
 
Loss of PINK1 prevents mitophagic elimination of 
damaged mitochondria 
 
To test whether PINK1-KO mouse embryonic 
fibroblasts (MEFs) constitute a useful model to dissect 
the role of mitophagy in the establishment of induced 
pluripotency, we first mimicked mitochondrial damage 
by experimentally depolarizing mitochondria [62]. To 
probe PINK1-dependent autophagic digestion of 
mitochondria (Supplemental Fig. 1A), we tracked the 
intracellular distribution of MitoTracker in PINK+/+ 
and PINK-/- MEFs upon treatment with the uncoupler 
carbonyl cyanide m-chlorophenylhydrazone (CCCP), a 
lipid-soluble weak acid that drastically increases 
proton permeability across the mitochondrial inner 
membranes, thus dissipating the transmembrane 




































MitoTracker becomes covalently bound to mito-
chondrial proteins after uptake and remains in 
mitochondria even if a mitochondrion subsequently 
depolarizes, loss of MitoTracker after mitophagy 
stimulation largely represents lysosomal digestion of 
mitochondrial peptide fragments or breakage of 
covalent bonds between MitoTracker and mitochondrial 
proteins [67].  
 
When we monitored mitochondrial clearance following 
treatment with 20 μmol/L CCCP for 18 h 
(Supplemental Fig. 1B, top panels), no MitoTracker-
labeled mitochondria were detected in 86±6% of 
PINK1+/+ MEFs (Supplemental Fig. 1C). In clear 
contrast, mitochondria were retained in PINK1-deficient 
cells (Supplemental Fig. 1B, bottom panels) and 
mitochondrial clearance occurred solely in a very small 
percentage (14±7%) of PINK1-/- MEFs following 







































sequential process of PINK1‐dependent mitophagy.  In  response  to several mitochondrial stresses,  including chemical uncoupling  (by
CCCP treatment), mtDNA mutations, increasing ROS levels, and other yet‐to‐be discovered stimuli (e.g., nuclear reprogramming), PINK1
becomes  stabilized  on  the  mitochondrial  outer  membrane  of  unwanted  or  damaged  mitochondria.  Association  of  PINK1  with
mitochondria  results  in  the  subcellular  distribution  and  translocation  of  the  ubiquitin  ligase  Parkin,  which  ubiquitinates  specific
mitochondrial surface proteins, such as mitofusins (Mfn1/2). Mitochondrial ubiquitination, in turn, results in the recruitment of adapter
proteins  including  p62/SQSTM1  and  HDAC6  that  ultimately  links  ubiquitinated  substrates  to  cellular  transport  and  autophagic
machineries.  This  transport  results  in  the  peri‐nuclear  clustering  and  formation  of mito‐aggresomes, which may  thereby  serve  to
restrict  cellular  distribution  of  unwanted  or  damaged  mitochondria  as  well  as  to  prepare  targeted  mitochondria  for  autophagic
clearance.  LC3  and  autophagosomal membranes  are  co‐recruited  during  transport  and  aggregation  of  targeted mitochondria  and,
consequently, mito‐aggresomes become engulfed by the forming autophagosomes that finally fuse with lysosomes for degradation and
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Indeed, CCCP treatment resulted in the formation of 
large MitoTracker-positive aggregates in PINK1-/- MEFs, 
mainly in the perinuclear region, with relatively sparse 
cytosolic staining (Supplemental Fig. 1B, bottom panels). 
We further confirmed this mitophagy defect by 
immunostaining with an antibody against the β1-subunit 
of the mitochondrial F1-ATPase complex, which strongly 
labeled mitochondrial aggregates in PINK1-/- MEFs 
(Supplemental Fig. 1B). Similarly, staining of 
p62/SQSTM1, an adapter protein that binds ubiquitinated 
mitochondria, was readily detectable in PINK1-/- MEFs, 










































Mitophagy deficiency-imposed roadblock for 
reprogramming is partially circumvented by vitamin 
C.  
 
Using 2'-7'-dichlorodihydrofluorescein diacetate 
(DCFH-DA) to measure ROS generation in the 
cytoplasm and cellular organelles such as the 
mitochondria, we noted a marked increase in oxidative 
stress in mitophagy-deficient PINK1-/- MEFs relative to 
mitophagy-competent PINK1+/+ MEFs following 
treatment with CCCP (Supplemental Fig. 2A). Indeed, 















































CCCP  (top). Measurement of ROS  in CCCP‐treated  cells  (bottom). Untreated or CCCP‐treated PINK1+/+ and PINK1‐/‐
MEFs were exposed for 60 min to H2DCF‐DA and fluorescence intensity was measured by flow cytometry. Shown are
representative scatter plot histograms of DCF  fluorescence.  (B) Measurement of ROS  in OSK‐transduced cells  (left).
Bar charts of representative measurements of ROS levels (% increase versus baseline ROS levels in untransduced MEF
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ROS during reprogramming revealed that both cell 
types displayed a marked burst of ROS at day 4 after 
OSK transduction, ROS production at this time was 
significantly greater in PINK1-/- MEFs compared with 
equivalent wild-type cells (Supplemental Fig. 2B, top).  
 
A testable prediction from this observation is that 
inhibition or alleviation of excessive ROS production 
should increase the number of mitophagy-deficient cells 
that surpass the early reprogramming barrier imposed 
by abnormal mitophagy. We therefore evaluated 
whether the ability of vitamin C to block steady-state 
ROS levels in OSK-transduced PINK1-/- MEFs might 
lead to an increase in reprogramming efficiency. 
Addition of vitamin C (50 μg/mL) notably increased the 
reprogramming efficiency of OSK-transduced PINK1-/- 
MEFs (Supplemental Fig. 2B, bottom); however, when 
both cell types were supplemented with vitamin C 
during reprogramming, OSK-transduced PINK1+/+ 
MEFs still generated significantly more colonies than 
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